Today, the U.S. Food and Drug Administration requested that Endo
Pharmaceuticals remove its opioid pain medication, reformulated Opana ER
(oxymorphone hydrochloride), from the market. After careful
consideration, the agency is seeking removal based on its concern that
the benefits of the drug may no longer outweigh its risks. This is the
first time the agency has taken steps to remove a currently marketed
opioid pain medication from sale due to the public health consequences
of abuse.
Learn More
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm562401.htm
http://fortune.com/2017/06/09/endo-pharmaceuticals-stock-fda/
https://www.healthnutnews.com/breaking-fda-calls-for-removal-of-dangerous-opioid-painkiller-from-the-market/
No comments:
Post a Comment